Trial Profile
A postmarketing surveillance study of natalizumab in patients with risk of progressive multifocal leukoencephalopathy
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Oct 2016
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- 14 Oct 2016 New trial record